| Stage | CMCSA | % of rev | LBRDK | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $29.3B | 100.00% | $246M | 100.00% | CMCSA ×119.10 |
| Gross profit | $21.8B | 74.35% | $246M | 100.00% | LBRDK +25.7pp |
| Operating income | $5.3B | 18.16% | $21M | 8.54% | CMCSA +9.6pp |
| Pre-tax income | $4.4B | 15.18% | $253M | 102.85% | LBRDK +87.7pp |
| Net income | $3.4B | 11.48% | $195M | 79.27% | LBRDK +67.8pp |
| Stage | CMCSA | LBRDK | Gap · A − B |
|---|---|---|---|
| Revenue | $29.3B100.00% | $246M100.00% | CMCSA ×119.10 |
| Gross profit | 74.35%$21.8B | 100.00%$246M | LBRDK +25.7pp |
| Operating income | 18.16%$5.3B | 8.54%$21M | CMCSA +9.6pp |
| Pre-tax income | 15.18%$4.4B | 102.85%$253M | LBRDK +87.7pp |
| Net income |
| 11.48%$3.4B |
| 79.27%$195M |
| LBRDK +67.8pp |
No disclosed counterparties: LBRDK.
None